During the 6th International Congress on Human Papillomavirus Infection and Global Prevention of Cervical Cancer organized by the European Research Organization on genital Infection and Neoplasia (EUROGIN) in Paris, mtm Laboratories AG announced the potential of p16INK4a as biomarker for cervical cancer screening and diagnosis.

Several studies presented at the meeting evaluated the potential use of the CINtec® p16INK4a-based immunocytochemistry protocol on cervical cytology preparations.

The results from these studies indicate the high potential of p16INK4a-based tests being developed into efficient diagnostic tools for the triage of abnormal Pap cytology results.

p16INK4a - a biomarker central to diagnostic and screening technologies is being developed by mtm Laboratories for cervical cancer.

Cervical cancer being the second most common cancer in women can be prevented 10o% when detected at the early stage. But current screening technologies and diagnostics for cervical cancer have limitations; they have a high degree of subjectivity and do not actually detect direct disease markers.

This is where mtm Laborataories AG come in by developing a family of screening and diagnostic technologies based on the p16INK4a biomarker which promises extreme precision, giving confident and accurate early diagnosis of cervical cancer.

Source: PR Newswire